Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Multiple Myeloma 3Triple Negative Breast Neoplasms 2Lymphoma, Non-Hodgkin 2Breast Neoplasms 2rrCLL 1Recurrence 1Pancreatic Neoplasms 1Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Breast Neoplasms, Male 1Advanced Malignant Solid Neoplasm 1

Interventions

Trastuzumab 8Paclitaxel 7Taxes 6Lapatinib 6Docetaxel 5veliparib 3Tamoxifen 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3sargramostim 2liposomal doxorubicin 2ixabepilone 2cediranib 2Vorinostat 2Vinorelbine 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2Mifepristone 2MK 2206 2Interleukin-12 Subunit p35 2Interleukin-12 2Granulocyte-Macrophage Colony-Stimulating Factor 2Goserelin 2Gemcitabine 2Filgrastim 2Everolimus 2Erlotinib Hydrochloride 2Doxorubicin 2Cyclophosphamide 2Cisplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Breast Neoplasms, Male × dinaciclib × Clear all
NCT01624441 2018-03-30

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Completed
40 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡